 |
|
|
| |
Efficacy and tolerability of simeprevir (TMC435) 150 mg once daily
with peginterferon and ribavirin for treatment of HCV genotype 1 infection in patients with Metavir score F3 and F4 (PILLAR and ASPIRE trials)
|
| |
| |
Reported by Jules Levin
AASLD 2012 Nov 10-14 Boston
Fred Poordad,1 Michael W. Fried,2 Stefan Zeuzem,3 Peter Ferenci,4
Oliver Lenz,5 Rekha Sinha,5 Katleen Callewaert,5 Monika Peeters,5
Maria Beumont-Mauviel5
1Cedars-Sinai Medical Center, Los Angeles, CA, USA; 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 3J.W. Goethe University Hospital, Frankfurt, Germany; 4Universitätsklinik für Innere Medizin III, Wien, Austria;
5Janssen Infectious Diseases BVBA, Beerse, Belgium
|
| |
|
|
|
|
|
